Skip to main content

Table 4 PTGS2 rs5275 genotype and breast cancer risk within the NHS1, NHS2, WHS, and pooled data

From: A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study

Study Genotype Cases (percentage) Controls (percentage) OR (95% CI)a
NHS1 T/T 541 (43.3) 699 (40.6) 1.00 (reference)
  T/C 567 (45.4) 808 (47.0) 0.89 (0.75–1.04)
  C/C 141 (11.3) 213 (12.4) 0.80 (0.62–1.03)
     p trend = 0.05
NHS2 T/T 140 (46.5) 270 (44.3) 1.00 (reference)
  T/C 131 (43.5) 259 (42.5) 0.97 (0.72–1.31)
  C/C 30 (10.0) 81 (13.3) 0.72 (0.45–1.15)
     p trend = 0.26
WHS T/T 281 (43.6) 278 (42.7) 1.00 (reference)
  T/C 296 (46.0) 294 (45.2) 0.99 (0.78–1.26)
  C/C 67 (10.4) 79 (12.1) 0.86 (0.58–1.25)
     p trend = 0.53
Pooled T/T 962 (43.8) 1,246 (41.8) 1.00 (reference)
  T/C 994 (45.3) 1,361 (45.7) 0.93 (0.82–1.05)
  C/C 238 (10.8) 373 (12.5) 0.80 (0.66–0.97)
     p trend = 0.02
  1. aUnconditional logistic regression controlled for age, age at first birth and parity, menopausal status at diagnosis, history of benign breast disease, and family history of breast cancer. CI, confidence interval; NHS, Nurses' Health Study; OR, odds ratio; PTGS2, prostaglandin endoperoxide synthase 2; WHS, Harvard Women's Health Study.